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Abstract
Background: Furosemide, a diuretic that acts on the loop of Henle, is commonly used to treat congestive heart
failure in veterinary medicine. Some owners have difficulty in administering oral tablet medication to animal
patients, which leads to noncompliance, especially during long-term administration. Oral disintegrating film (ODF)
has the advantages of easy administration via a non-invasive route, rapid dissolution, and low suffocating risk. The
objective of this study was to research the pharmacokinetic (PK) profiles and diuretic effect of furosemide after
intravenous (IV), orally uncoated tablet (OUT), and newly developed ODF administration in healthy beagle dogs. In
this study, a furosemide-loaded ODF (FS-ODF) formulation was developed and five beagle dogs were administered
a single dose (2 mg/kg) of furosemide via each route using a cross-over design.
Results: The most suitable film-forming agent was sodium alginate; thus, this was used to develop an ODF for easy
drug administration. No significant differences were detected in the PK profiles between OUT and FS-ODF. In the
blood profiles, the concentration of total protein was significantly increased compared to the baseline (0 h),
whereas no significant difference was detected in the concentration of creatinine and hematocrit compared to the
baseline. FS-ODF resulted in a similar hourly urinary output to OUT during the initial 2 h after administration. The
urine specific gravity was significantly decreased compared to the baseline in each group. The peak times of urine
electrolyte (sodium and chloride) excretion per hour were 1 h (IV), 2 h (OUT), and 2 h (FS-ODF).
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Conclusions: These results suggest that the PK/PD of furosemide after administration of newly developed FS-ODF
are similar to those of OUT in healthy dogs. Therefore, the ODF formulation has the benefits of ease and
convenience, which would be helpful to owners of companion animals, such as small dogs (< 10 kg), for the
management of congestive heart failure.
Keywords: Canine, Furosemide, Loop diuretic, Oral film, Tablet, Conventional administration, Congestive heart
failure, Diuresis, Noncompliance
Background
Furosemide, a diuretic commonly used in veterinary and
human medicine, is recommended as first-line therapy
in the management of congestive heart failure (CHF) [1,
2]. It is used in animals for the treatment of pulmonary
edema, udder edema, hypercalciuric nephropathy,
uremia, and hypertension. Additionally, it reduces the
incidence of sterile hemorrhagic cystitis associated with
cyclophosphamide administration in dogs and is used as
adjunctive therapy in hyperkalemia [2–10]. The pharma-
cokinetics and pharmacodynamics properties of loop di-
uretics, including furosemide after IV and oral (PO)
administration, have been well investigated in both hu-
man and veterinary medicine [5, 8, 11–14].
Furosemide decreases the absorption of electrolytes in
the luminal surface of the thick ascending loop of Henle
via the deactivation of the Na+-K+-2Cl− cotransporter.
Thus, this drug increases the renal excretion of sodium,
potassium, chloride, and water [8]. Additionally, fur-
osemide causes renal venodilation, increases glomerular
filtration rate, increases renal blood flow, and decreases
peripheral resistance. Furthermore, furosemide activates
the renin-angiotensin-aldosterone-system and sympa-
thetic nervous system [15–17]. Although furosemide in-
creases renin secretion, owing to its effects on the
nephron, increases in sodium and water retention do
not occur [8].
Conventional routes of furosemide administration are
intravenous (IV), intramuscular (IM), subcutaneous
(SC), or oral (PO). Unless an acute heart failure event
occurs, PO administration is indicated in most cases that
require long-term use in stable patients [8, 9, 18]. The
onset time (IV, 5 min), elimination half-life (IV, 1–
1.5 h), duration (IV, 3–6 h), and peak urine output (IV
and SC, 1 h; PO, 2 h) of furosemide have been shown in
previous experiments in dogs [8].
However, some owners have difficulty administering
oral tablet medications, which leads to noncompliance,
especially with drugs that require long-term administra-
tion. Particularly with cats, it is often difficult to admin-
ister pills or capsules. Beyond the conventional
administration routes and formulations, studies have
been conducted to identify options with similar efficacy
that can be easily administered. For human cardiac dis-
ease, these studies have led to the development of the
sildenafil citrate sublingual tablet to treat pulmonary ar-
terial hypertension, nitroglycerin ointment to treat CHF,
transdermal tulobuterol patch for bronchodilation, and
transdermal beta-blocker (bisoprolol) patch to reduce
postoperative atrial fibrillation [19–22].
The oral disintegrating film (ODF) offers several bene-
fits especially in children, including easy administration
via a non-invasive route, fast dissolution, and no risk of
choking [23], that also can be utilized in veterinary
medicine. Moreover, sublingual and oral furosemide ad-
ministration differ in pharmacokinetic and pharmacody-
namic results in humans [11]; the sublingual route may
provide therapeutic advantages over the oral route, espe-
cially in patients with CHF. In veterinary medicine, there
is a study on the diuretic effect of furosemide according
to the IV, SC, PO, and constant rate infusion (CRI)
routes in dogs [18]. The study on furosemide adminis-
tration using sublingual bioadhesive film showed ex vivo
mucoadhesion using the buccal mucosa and permeabil-
ity using the tongue excised from slaughtered pigs [24].
And no alternative route of administration of furosemide
has been reported, except for a study that the thera-
peutic effect of the transdermal application of furosem-
ide to cats is negligible [7]. However, there are no
announced studies on alternative administration routes
in dogs. Despite there is a need for formulations that
can be safely administered to and easily absorbed by ani-
mals, ODFs for use in dogs (especially small dogs) and
cats have not been developed.
The first objective of this study was to develop a suit-
able film applicable containing furosemide, which pro-
vide advantages over conventional administration routes
in veterinary medicine. The second objective of this
study was to compare the PKs and diuretic effect of fur-
osemide after newly developed furosemide-loaded ODF
(FS-ODF), conventional oral commercial tablet, and IV
administration. We hypothesized that the newly devel-
oped FS-ODF would have similar drug when compared
to oral tablets when administered at the same dose. .
Results
Based on previous studies, film-forming agent and other
excipients, including the plasticizer, solubilizer, disinte-
grant, sweetener, and solvent, were investigated for the
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most suitable agent and sodium alginate was selected to
form the ODF.
The FS-ODF was prepared using the formulation
shown in Table 1. Each FS-ODF had a size of 2 × 3 cm2
and weight of each film is 50 mg. This film had a homo-
geneous surface with some turbidity (Fig. 1). The mean
weight of the film and drug content were 51.75 ±
2.25 mg and 97.63 % ± 1.87 %, respectively The disinte-
gration time was 33.5 ± 4.5 s in water and the bending
count, which represents tensile strength, was 4.4 ± 0.5.
In the dissolution test, FS-ODF showed a pH-
dependent curve (Fig. 2). The dissolution rate at pH 4.0
(96.75 %) and pH 6.8 (98.48 %) was higher than that at
pH 1.2 (3.54 %) after 60 min. The dissolution rate at pH
1.2 was less than 10 % after 120 min. However, FS-ODF
reached complete dissolution of more than 95 % at pH
4.0 and pH 6.8 within 60 min.
The dose of furosemide via all three routes was well-
tolerated in all dogs. The vital signs on physical examin-
ation and behavior did not change during the study period.
PK data of furosemide after the three routes of admin-
istration are summarized in Table 2 and presented in
Fig. 3. No significant differences were detected between
the orally uncoated tablet (OUT) and FS-ODF. In our
study, the PK results of plasma furosemide showed a
mean Cmax of 9.65 µg/mL (IV, C0), 0.61 µg/mL (OUT),
and 0.81 µg/mL (FS-ODF), mean AUClast of 2.67 µg·h/
mL (IV), 1.16 µg·h/mL (OUT), and 1.11 µg·h/mL (FS-
ODF), and mean T1/2 of 2.07 h (IV), 3.44 h (OUT), and
2.64 h (FS-ODF).
Plasma concentration of total protein was significantly
increased 4 h after IV, 1–4 h after OUT, and 2–4 h after
FS-ODF administration compared to baseline. However,
the plasma blood urea nitrogen (BUN) concentration was
significantly increased 1–2 h after IV and decreased 1 h
and 4–8 h after FS-ODF administration compared to
baseline. The plasma concentrations of creatinine and
hematocrit were not significantly different compared to
the baseline at any time point (Table 3). Moreover, the
serum potassium concentration was significantly de-
creased 1–6 h after IV and OUT and 1–8 h after FS-ODF
administration, and the serum chloride concentration was
significantly decreased 2 h after IV and OUT administra-
tion. Compared to that at baseline, the serum sodium con-
centration did not change significantly over time (Table
4). Additionally, indirect systolic blood pressure was not
different among application routes nor time points.
The hourly urine output (HUO) and accumulated
urinary output are shown in Table 5. The HUO in the
1–2 h after administration was increased significantly
compared to the baseline in each group. The HUO peak
of IV administration was high and early, whereas that of
OUT and FS-ODF administration was broader and ap-
peared later. The HUO was increased 1 h after IV ad-
ministration, then returned to the baseline level after
4 h. The HUO for OUT and FS-ODF was increased 1–
2 h after administration and returned to the baseline
level after 6 h. The mean duration of diuresis until the
return to baseline levels after IV, OUT, and FS-ODF ad-
ministration was 4.1 h, 5.72 h, and 5.24 h, respectively.
Similar value of HUO were observed between OUT and
FS-ODF during initial 2 h after administration. The total
urine output was 24.65 mL/kg, 30.9 mL/kg, and 25.4
mL/kg during 8 h after IV, OUT, and FS-ODF adminis-
tration, respectively. -Urine-specific gravity (USG) and
urine electrolyte excretion per hour (UEEH) are shown in
Table 1 Formulation of FS-ODF
Purpose of use Formulation (mg)
Acitive ingredient Furosemide 20
Film forming agent Sodium alginate 14
Plasticizer Glycerin 4
PEG 400 4
Solubilizer Tween 80 1
Sweetener D-Sorbitol 1
Disintegrant Crospovidone 6
Total weight (mg) 50
Fig. 1 Representative appearance of furosemide-loaded orally
disintegrating film. Legend: No content
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Table 6. The USG was significantly decreased after admin-
istration in all groups but returned to the baseline after
8 h. The UEEH was significantly increased 1–2 h after ad-
ministration in all groups. The peak times of sodium and
chloride UEEH were 1 h, 2 h, and 2 h, whereas those of
potassium UEEH were 1 h, 1 h, and 2 h, after IV, OUT,
and FS-ODF administration, respectively.
Discussion
To the authors’ knowledge, this study is the first to com-
pare the PK parameters and diuretic effect of IV, OUT
and ODF administration of furosemide in dogs. Among
the conventional routes of furosemide administration,
PO administration is the most common route for long-
term management in veterinary patients with CHF [8,
9]. However, in the case of home care, oral tablet admin-
istration may be limited by low patient cooperation and
it is difficult to use other traditional administration
routes, such as IM, SC, and IV. For the reasons men-
tioned earlier, we studied a useful alternative routes that
could be applied to veterinary medicine.
Usually, ODFs disintegrate within 1 min in the oral
cavity owing to contact with the saliva, which results in
rapid absorption. Furthermore, when administered via
buccal or sublingual routes, there are advantages of high
Fig. 2 Dissolution profiles of furosemide-loaded orally disintegrating film at pH 1.2, pH 4.0, pH 6.8. (n = 4). Legend: No content
Table 2 Pharmacokinetic parameters of furosemide (2 mg/kg) based on route of administration in beagle dogs
Pharmacokinetic parameters IV OUT FS-ODF P
OUT vs. FS-ODF
Cmax (μg/mL) 9.65 ± 1.63 (10.35) 0.61 ± 0.31 (0.69) 0.81 ± 0.81 (0.58) 0.619
Tmax (h) 0.00 1 (0.5-1.5) 0.75 (0.25-1) 0.130
T1/2 (h) 2.07 ± 0.76 (1.63) 3.44 ± 1.79 (2.86) 2.64 ± 0.75 (2.46) 0.602
MRT (h) 0.90 ± 0.25 (0.78) 5.08 ± 1.67 (4.13) 3.47 ± 0.76 (3.55) 0.128
AUCinf (μg·h/mL) 2.74 ± 0.25 (2.60) 1.50 ± 0.73 (1.72) 1.25 ± 0.68 (1.34) 0.493
AUClast (μg·h/mL) 2.67 ± 0.26 (2.56) 1.16 ± 0.46 (1.44) 1.11 ± 0.63 (1.08) 0.734
CL (mL/h/kg) 735.7 ± 63.84 (768.98) - - -
Vss (mL/kg) 667.5 ± 222.6 (597.82) - - -
BA (%) - 54.98 ± 26.51 (62.74) 45.73 ± 25.02 (48.82) 0.493
Cmax maximum plasma concentration, Cmax,IV = C0, Tmax time at the maximum concentration, T1/2 elimination half-life, MRT mean residence time, AUCinf area under
the curve from time zero to time of infinity measurable concentration, AUClast area under the curve from time zero to time of last measurable concentration, BA
bioavailability, CL elimination clearance, Vss volume of distribution at steady state, IV intravenous, OUT orally uncoated tablet, FS-ODF furosemide-loaded orally
disintegrating film. Results are presented as mean ± SD (median). However, Tmax, a categorical variable, expressed as median and range. (*), values are
significantly different (P < 0.05); (**) values are significantly different (P < 0.01)
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permeability and bypassing first-pass metabolism [23].
In this study, the ODF dissolved in the mouths of dogs
quickly without water, which indicates that the ODF for-
mulation is beneficial with regard to rapid dissolution,
absorption, and ease of drug administration in veterinary
patients. Therefore, a low-dose FS-ODF formulation for
small animals was developed.
Based on our research results, it was decided to use
sodium alginate as film-forming agent containing fur-
osemide. Then, 20 mg of furosemide (a high ratio; 40 %,
w/w) was loaded per sheet, which was cut depending on
the body weight of the dog to reach a dose of 2 mg/kg.
These physical specifications were achieved for conveni-
ence of use in small animals, such as small dogs (<
10 kg) or cats [25]. The small and uniform particles of
furosemide in the final preparation suspension enabled
the homogeneous and desirable film surface and might
have reduced weight variation and content loss [26]. The
formulation was optimized, with a disintegration time of
less than 40 s, owing to the presence of crospovidone as
a disintegrant. Rapid disintegration to small particles in
the mouth is an essential property to ensure the good
usability of a film [27]. Moreover, the bending count was
in an acceptable range and showed the flexibility of the
film. Overall, FS-ODF had suitable film properties in
terms of appearance, drug content, disintegration time,
and tensile strength.
In the dissolution test, FS-ODF showed a pH-
dependent curve because furosemide has a highly pH-
dependent solubility. Furosemide is a weak acid (pKa =
Fig. 3 Mean plasma furosemide concentration for each group. Legend: A Comparison of time course change in plasma concentration following
2 mg/kg furosemide administration in intravenously (IV), orally uncoated tablet (OUT) and furosemide-loaded orally disintegrating film (FS-ODF)
group. B OUT and FS-ODF are represented by a line graph in (A). IV, (●); OUT, (□); FS-ODF, (◇)
Table 3 Hematocrit and biochemistry profile following single dose of furosemide (2 mg/kg) administration
Baseline Time (h)
1 2 4 6 8
Hematocrit(%) IV 40.46 ± 9.43 41.36 ± 5.43 38.52 ± 6.84 39.06 ± 7.43 39.02 ± 6.01 40.22 ± 5.35
OUT 38.98 ± 4.18 39.10 ± 3.16 38.52 ± 3.50 38.64 ± 3.75 38.72 ± 4.04 40.12 ± 3.94
FS-ODF 41.94 ± 5.19 41.02 ± 6.17 40.20 ± 6.48 41.44 ± 4.21 41.58 ± 6.30 40.54 ± 7.81
BUN (mg/dL) IV 17.10 ± 6.33 17.50 ± 5.60** 17.20 ± 5.57** 16.72 ± 5.25 16.20 ± 5.21 15.94 ± 5.23
OUT 21.84 ± 9.99 20.82 ± 9.12** 20.22 ± 8.99 19.04 ± 7.96 17.52 ± 6.25 16.60 ± 5.83
FS-ODF 18.96 ± 6.39 18.68 ± 6.15** 18.16 ± 6.10 17.30 ± 5.90** 16.14 ± 5.28* 15.41 ± 4.72*
Cr (mg/dL) IV 0.72 ± 0.24 0.68 ± 0.19 0.68 ± 0.24 0.68 ± 0.19 0.72 ± 0.13 0.68 ± 0.23
OUT 0.72 ± 0.29 0.70 ± 0.25 0.68 ± 0.23 0.66 ± 0.23 0.68 ± 0.16 0.66 ± 0.18
FS-ODF 0.72 ± 0.13 0.74 ± 0.19 0.68 ± 0.22 0.70 ± 0.19 0.72 ± 0.19 0.70 ± 0.20
Total protein (mg/dL) IV 5.90 ± 0.36 6.32 ± 0.29** 6.18 ± 0.36** 6.10 ± 0.30* 6.04 ± 0.25 6.04 ± 0.34*
OUT 5.74 ± 0.29 6.02 ± 0.25** 6.10 ± 0.38** 6.10 ± 0.31* 5.94 ± 0.34 6.00 ± 0.29*
FS-ODF 6.06 ± 0.18 6.30 ± 0.10** 6.38 ± 0.18** 6.26 ± 0.17* 6.30 ± 0.20 6.34 ± 0.05*
Data are described as mean ± SD values. IV intravenous, OUT orally uncoated tablet, FS-ODF furosemide-loaded orally disintegrating film, BUN Blood urea nitrogen,
Cr Creatinine. The p-values are significantly different (*p < 0.05, **p < 0.01) compared to the baseline
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3.48) with a carboxylic acid functional group and its
aqueous solubility increases as the pH increases from
0.18 mg/mL (pH 2.3) to 13.36 mg/mL (pH 10.0) [28].
Thus, in this study, the dissolution rate was in the order
of pH 6.8 > pH 4.0 > > pH 1.2 within 60 min. FS-ODF
showed immediate-release on the curve (Fig. 2), with
high dissolution rates at pH 4.0 and pH 6.8 owing to the
rapid disintegration time of less than 1 min. Therefore,
FS-ODF was sufficient, in terms of disintegration time
and dissolution rate, for administration to small animals.
In dogs and humans, the diuretic effect caused by fur-
osemide continues for 3 h after IV injection. The con-
centration of furosemide initially exceeds the number of
Na+-K+-2Cl− cotransporters in the loop of Henle after
IV administration and are excreted in the urine. There-
after, the furosemide concentration declines under
therapeutic concentrations [29–31].
Additionally, the bioavailability of furosemide is differ-
ent depending on the administration method. For ex-
ample, when administered orally, the first-pass effect,
related to the extent of gastrointestinal absorption and
metabolism, plays a major role in the bioavailability of
furosemide. Also, the first-pass effect varies by species
and individual. The diuretic effect of furosemide after
PO administration has a slower onset than that after IV
and SC administration [32]. Furthermore, the bioavail-
ability of furosemide is approximately 77 % in dogs and
60–65 % in humans after PO administration [8, 13, 29].
The diuretic effect of furosemide continues 1–2 h after
IV injection. Moreover, the absorption of furosemide is
influenced by the pH and the existence of binding pro-
teins in the stomach [18, 33, 34]. Although furosemide is
slowly absorbed in the small intestine, it is absorbed rap-
idly in the stomach because of the acid environment.
The absorption of furosemide in the gastrointestinal
tract of patients with CHF may be lower than normal
[35]. Generally, in patients with CHF, absorption delay
may be the result of increased motility, reduced perfu-
sion, or mucosal edema of intestine [36, 37].
The PKs of furosemide determine the therapeutic ef-
fect, entry rate of drug into the blood and urine, and on-
set and duration of effects, all of which are altered by
the method of administration [18, 29, 30]. Both OUT
and FS-ODF administration showed a slower onset and
a longer elimination half-life than IV administration.
Previous studies have shown a half-life of 0.5–1 h after
IV administration, whereas the half-life has been re-
ported as 30 min in the major disposition phase and
Table 4 Serum electrolyte concentration following furosemide (2 mg/kg) administration in beagle dogs
Baseline Time (h)
1 2 4 6 8
Serum sodium excretion (mmol) IV 151.26 ± 4.06 148.14 ± 1.46 148.04 ± 1.13 150.60 ± 2.10 147.74 ± 4.79 148.52 ± 1.30
OUT 150.34 ± 2.62 153.56 ± 7.59 150.14 ± 1.48 149.12 ± 1.08 151.92 ± 5.29 149.84 ± 1.44
FS-ODF 150.94 ± 2.97 155.20 ± 9.26 150.06 ± 2.12 148.98 ± 6.06 153.46 ± 9.29 148.56 ± 1.09
Serum potassium excretion (mmol) IV 4.48 ± 0.15 4.19 ± 0.17* 3.97 ± 0.29** 4.12 ± 0.29** 4.04 ± 0.31** 4.15 ± 0.42
OUT 4.51 ± 0.34 4.43 ± 0.41* 3.97 ± 0.14** 4.05 ± 0.23** 4.04 ± 0.28** 4.05 ± 0.27
FS-ODF 4.43 ± 0.32 4.08 ± 0.36** 3.92 ± 0.28** 4.09 ± 0.37** 4.13 ± 0.41* 4.05 ± 0.23*
Serum chloride excretion (mmol) IV 110.66 ± 4.20 106.46 ± 1.41 105.96 ± 1.33* 107.64 ± 2.01 104.34 ± 4.25 106.36 ± 0.80
OUT 110.28 ± 3.38 111.56 ± 8.26 107.52 ± 1.61* 105.88 ± 0.58 107.76 ± 3.43 106.50 ± 1.35
FS-ODF 110.22 ± 3.30 112.74 ± 7.69 106.84 ± 1.82 106.04 ± 4.56 109.96 ± 7.89 106.20 ± 1.08
Results are presented as mean ± SD. IV intravenous, OUT orally uncoated tablet, FS-ODF furosemide-loaded orally disintegrating film. The p-values are significantly
different (*p < 0.05, **p < 0.01) compared to the baseline
Table 5 Hourly urine output and cumulative urine output after furosemide administration via different routes
Baseline Time (h)
1 2 4 6 8
Hourly urinary output (ml/h) IV 8.45 ± 2.82 147.20 ± 34.05** 74.60 ± 15.61** 9.70 ± 3.93 7.10 ± 3.11 6.20 ± 3.68
OUT 16.40 ± 22.28 88.80 ± 94.10** 128.80 ± 51.09** 34.30 ± 16.90 13.50 ± 5.51 6.60 ± 4.59
FS-ODF 12.66 ± 6.97 71.40 ± 41.93* 121.20 ± 61.49* 18.0 ± 8.96 9.40 ± 4.48 6.70 ± 2.31
Accumulatedurinary output (ml) IV 13.0 ± 4.53 160.20 ± 37.16** 234.80 ± 47.07** 254.20 ± 51.28** 268.4 ± 57.05** 288.6 ± 55.76**
OUT 26.20 ± 32.22 115.0 ± 124.80** 243.80 ± 151.63** 312.40 ± 139.36** 339.4 ± 135.60** 359.8 ± 134.75**
FS-ODF 27.0 ± 16.90 98.40 ± 41.97* 219.60 ± 89.41** 255.60 ± 91.68** 274.40 ± 87.68** 293.60 ± 99.60**
Data are described as mean ± SD values. IV intravenous, OUT orally uncoated tablet, FS-ODF furosemide-loaded orally disintegrating. The p-values are significantly
different (*p < 0.05, **p < 0.01) compared to the baseline
Koh et al. BMC Veterinary Research          (2021) 17:295 Page 6 of 11
approximately 7 h in the slow elimination phase after
PO administration in dogs [5, 6, 38]. According to an-
other PK/PD study in healthy beagle dogs, the half-life
after PO administration in dogs is 3 h, which is similar
to the results of the present study [39].
In the body, furosemide moves across the renal tu-
bule from the plasma to the lumen of the nephron;
thus, furosemide acting on henle’s loop of renal tu-
bule should have a short duration of effects if its
half-life is short [7]. These results appear to be owing
to the initial high blood concentration and rapid
elimination of furosemide after IV administration. In
addition to the route of administration of the drug, it
should also be considered that the half-life of drugs is
affected by many factors, including illness status, age,
and other physiological variables [40]. The present
study demonstrates that the PKs after the administra-
tion of FS-ODF are similar to those after that of
OUT in healthy dogs.
Furthermore, after IV administration, the HUO was
significantly increased and peaked after 1 h, then de-
creased gradually to baseline levels. This result was simi-
lar to that of previous studies of the IV route [8]. The
HUO of OUT and FS-ODF routes were significantly in-
creased after 1–2 h and peaked after 2 h. Therefore, FS-
ODF and OUT resulted in a similar HUO during the ini-
tial 2 h after administration.
The duration of diuresis (time until return to baseline
level after furosemide administration) after OUT and
FS-ODF administration was similar at 5 h. Additionally,
UEEHs were increased during the initial 2 h after admin-
istration in all groups. Based on HUO, USG, and UEEH
results, FS-ODF has equivalent aquaretic, natriuretic,
kaliuretic, chloriuretic, and diuretic effects to conven-
tional OUT.
This study has a few limitations, which may be over-
come by further research. First, additional studies using
different doses and repeating doses are needed because
we used only a single dose of furosemide (2 mg/kg). Sec-
ond, we only used five healthy intact beagle dogs. Add-
itional studies should be conducted in more dog patients
with CHF, renal failure, and delayed intestinal absorp-
tion. Third, since small animals have various body
weight ranges, it is necessary to prove that they contain
a homogeneous dose even when the film is cut to apply
the recommended diuretic dose.
Conclusions
In this study, we developed an ODF for small animals
that showed similar PK parameters and diuretic effect
when compared to OUT administration. Collectively,
the results of this study suggest that the FS-ODF formu-
lation can be used as an alternative to oral tablets in ani-
mal patients with heart failure and volume overload.
Therefore, it would be helpful to owners of dogs that re-
fuse conventional oral medications owing to the poten-
tial benefits of easy administration and convenient
dosage form.
Table 6 Urine-specific gravity and urine electrolyte excretion after furosemide (2 mg/kg) administration
Baseline Time (h)
1 2 4 6 8


































Urine sodium excretion per hour (mmol/h) IV 0.64 ± 0.56 17.75 ± 7.21** 8.70 ± 3.52** 0.95 ± 0.47 0.52 ± 0.21 0.35 ± 0.21




3.77 ± 1.77 1.22 ± 0.52 0.44 ± 0.22
FS-
ODF
0.93 ± 0.56 8.63 ± 4.63* 17.18 ± 12.01* 1.96 ± 0.94 0.78 ± 0.24 0.48 ± 0.11
Urine potassium excretion per hour (mmol/
h)
IV 0.31 ± 0.16 3.51 ± 1.17** 1.11 ± 0.32** 0.21 ± 0.10 0.16 ± 0.06 0.16 ± 0.11
OUT 0.92 ± 1.12 4.48 ± 4.48** 2.46 ± 1.24** 0.63 ± 0.26 0.33 ± 0.18 0.14 ± 0.06
FS-
ODF
0.79 ± 0.53 2.40 ± 0.67* 2.70 ± 1.38* 0.41 ± 0.21 0.24 ± 0.13 0.16 ± 0.06
Urine chloride excretion per hour (mmol/h) IV 0.43 ± 0.11 11.43 ± 3.04** 5.72 ± 1.33** 0.72 ± 0.33 0.32 ± 0.12 0.19 ± 0.08**
OUT 1.04 ± 1.29 8.48 ± 9.14** 10.29 ± 4.41** 2.63 ± 1.36 0.84 ± 0.38 0.25 ± 0.09**
FS-
ODF
0.76 ± 0.47 4.89 ± 2.62* 9.60 ± 5.21* 1.39 ± 0.62 0.53 ± 0.23 0.30 ±0.09
Data are described as mean ± SD values. IV intravenous, OUT orally uncoated tablet, FS-ODF furosemide-loaded orally disintegrating film. The p-values are
significantly different (*p < 0.05, **p < 0.01) compared to the baseline
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Methods
Animals
Five clinically healthy adult beagle dogs (three intact
males and two intact females) dogs from a research col-
ony at the College of Veterinary Medicine of Chungnam
National University were included in this study. The ani-
mals were 5–9 years of age and weighed 10–13 kg. All
dogs were normal on physical examination, including
systemic blood pressure measurement with a Doppler
device, and within normal ranges on complete blood
count, serum biochemistry panel, serum electrolytes,
and urinalysis. Animals were housed in cages and fed
commercial food (SUNGBO Pet Healthcare, Seoul,
South Korea) twice daily. Water was provided ad libi-
tum. This study was approved by the Institutional Ani-
mal Care and Use Committee (IACUC) at Chungnam
National University (approval number, CNU-01189).
After the study, all dogs were adopted as companion
animals.
Preparation of FS-ODF
The FS-ODFs were prepared by a simple, easy solvent-
casting method that required no special equipment [41].
For lab-scale preparation, as the batch size was 15 FS-
ODFs, the amount of formulation for 15 FS-ODFs was
weighed and used (Table 1). Furosemide and two plasti-
cizers were dissolved in 4.5 mL of ethanol, heated in
80 °C chambers for 30 min. This solution was trans-
ferred to a 40 °C chamber to reach temperature equilib-
rium (Solution A). The other excipients, including the
film-forming agent, solubilizer, and sweetener, were dis-
solved in 10.5 mL of water and the disintegrant was sus-
pended. This aqueous solution was transferred to 40 °C
chambers to reach temperature equilibrium (Solution B).
Solution A was added to Solution B and the mixture was
stirred at room temperature (22–24 °C) for 30 min to
obtain a uniform suspension. This suspension was soni-
cated for 10 min for degassing. The amount of suspen-
sion equivalent to 10.60 films on an area basis was
placed on a Petri dish (9 cm in diameter) and dried in
80 °C chambers for 40–45 min. The formed film was
peeled off and cut to a predetermined size of 2 × 3 cm2.
Characterization of FS-ODF
Disintegration time, bending count, weight and drug
content tests for characterization of FS-ODF were each
run 5 times.
Disintegration Time
One FS-ODF was placed on a petri dish (9 cm diameter)
with 15 mL of 37 ℃ water. The time to disintegrate
completely was measured by visual observation [42]. The
absence of any significant floating fragments was consid-
ered to be the completion of disintegration.
Bending Count
The bending count measured by the number of times it
took to split when the film was folded in half repeatedly
with two fingers.
Weight and Drug Content
The prepared FS-ODF was weighed using balance and
transferred into 30 mL dilution solution (0.05 N NaOH
solution) in 50 mL volumetric flask and dissolved with
vortexing. Then, the dilution solution was added to the
total volume. This solution of 2 mL was transferred to
100 mL volumetric flask and the dilution solution was
added to the total volume. The final solution was filtered
with syringe filter (0.45 μm) and the filtrate was analyzed
by the below HPLC method.
HPLC Condition
The HPLC analysis of furosemide in the samples was
conducted using a Waters 2695 HPLC system (Waters,
Milford, MA, USA) equipped with a UV-Vis detector
(Waters 2487, Waters, Milford, MA, USA). Furosemide
was analyzed using the reverse column with C18, 5 μm,
4.5 mm × 25 cm (Shiseido, Tokyo, Japan). The mobile
phase consisted of water, tetrahydrofuran, and acetic
acid (70:30:1, v/v/v). The HPLC analysis was performed
with a flow rate of 1.2 mL/min. The injected volume of
the sample was 20 µL, and UV detection was monitored
at 272 nm [43]. Data acquisition and processing were
carried out using the Waters LC Solution software.
Dissolution Test
The dissolution test was performed using the USP [35]
dissolution apparatus II at pH 1.2 (0.1 N HCl/NaCl buf-
fer), pH 4.0 (acetate buffer), pH 6.8 (phosphate buffer)
with the media volume of 900 mL at 37.0 ± 0.5 °C. The
rotational speed was adjusted to 50 rpm. The prepared
FS-ODF containing furosemide 20 mg in a sample was
placed into a dissolution vessel with a sinker [44]. At
each predetermined interval, the aliquot (5 mL) of the
medium was collected and filtered through a membrane
filter (pore size: 0.45 μm). The concentration of fur-
osemide in the filtrate was determined using the above
HPLC method.
Study design
This study was performed using a single-dose, random-
ized, 3-way crossover design. Three methods of furosem-
ide administration were used in each subject with at
least 7-day washout period between each experiment.
Animals were fasted for 12 h before the administration
of furosemide and had a free access to water during the
experiment.
Each (random) animals received a furosemide of 2 mg/
kg via intravenous (IV), orally uncoated tablet (OUT),
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furosemide-loaded orally disintegrating film (FS-ODF)
routes: (1) Furosemide 2 mg/kg IV (n = 5), (2) OUT for-
mulation of furosemide 2 mg/kg orally (n = 5), (3) FS-
ODF formulation 2 mg/kg orally (n = 5).
Injections and OUT formulation of furosemide were
purchased from handok Pharm. Co. (Seoul, South
Korea). For oral administration, furosemide OUT and
FS-ODF formulation were cut according to body weight
of each dog. Also, 22-Gauge IV catheter was used in the
cephalic vein for the IV injections. All dogs received no
other medications before the experiment and during the
washout period.
Sample collection
Blood samples were collected at 0 (serving as baseline),
5, 15, 30, 45, 60, 120, 240, 360, 480 min in each adminis-
tration routes. All blood samples were obtained from the
jugular vein with 23-Gauge 5mL syringe. These samples
were immediately divided into heparinized tubes for bio-
chemical test, plain tubes for electrolyte analysis and
EDTA-K2 tube for hematocrit. Heparinized plasma and
serum were separated after centrifugation at 3,000 x g
for 15 min and stored at − 20 °C until analysis. A
complete blood count, BUN, creatinine (Cr), plasma
total protein and serum electrolytes were measured.
The urine samples were collected at 0 (serving as base-
line), 1, 2, 4, 6, 8 h in each administration routes. In line
with previous studies, the bladder was initially emptied
2 h before baseline and then collected in 2 h to calculate
baseline hourly urine output (HUO) before furosemide
administration. An indwelling 6–8 Fr balloon Foley cath-
eter was placed into the urinary bladder at the initiation
of each experiment and the bladder was emptied for
urine volume measured at each time point. Urine sample
was centrifuged (1500 × g, 10 min) and the supernatant
was collected to verify urine-specific gravity and the con-
centrations of sodium, potassium and chloride.
Complete blood count was measured by ADVIA 2120i
(SIEMENS corporation, Munich, Germany) and bio-
chemistry were measured by Mindray BS-300 (Bio-Med-
ical Electronics Co., Ltd, Shenzhen, China). Electrolyte
concentrations in plasma and urine sample were mea-
sured by EasyLyte PLUS (MEDICA corporation, Bed-
ford, USA).
Quantification of furosemide in plasma
Plasma concentration of furosemide were determined by
HPLC-MS/MS system. To prepare appropriate assay
samples, plasma samples were processed with aceto-
nitrile to induce precipitation of plasma protein. Firstly,
15 µL of plasma or calibrator sample were treated with
155 µL of 0.11 µg/mL ibuprofen (internal standard, IS)
in acetonitrile. And then, sample mixtures were vigor-
ously shaken by vortex mix for 15 min. Finally, sample
mixtures were separated into supernatant and precipi-
tant pellet by centrifugation at 17,600 g for 15 min.
Standard samples were prepared by spiking of 5 µL
working solution (as furosemide; 0, 30, 100, 300, 1,000,
3,000, 10,000, 30,000, and 100,000 ng/mL in acetonitrile)
into 45 µL of blank plasma. For a sample analysis, 130
µL of supernatant were transferred into sample vials,
and 5 µL of processed sample was directly injected into
HPLC separation system.
Furosemide and IS were separated by Agilent 1100
HPLC system. Chromatographic separation was con-
ducted on Agilent ZORBAX® phase phenyl column
(5 μm, 2.1 × 50 mm) by 6 mM ammonium formate in
40 % acetonitrile solution.
After separation, both analytes were detected by triple
quadrupole mass spectrometer (AB SCIEX API4000
QTRAP®). Furosemide and IS were monitored under
electrospray ionization negative mode as multiple reac-
tion monitoring, which mass to charge ratio of 329.08−
to 284.80− for furosemide and 205.05− to 161.10− for IS,
respectively.
Peak areas integration and quantification were auto-
matically conducted by using Analyst software® (AB
Sciex) 1.6.2. The retention times of furosemide and ibu-
profen were 0.53 and 0.77 min, respectively.
Concentration-response of furosemide was linear at
ranges from 30 ng/mL to 10 µg/mL (r = 0.9971). The
validation values, including the precision (coefficient of
variance < 5.67 %), accuracy (relative error < 6.39 %) of
the measurements, were within the acceptable ranges
given by FDA guidelines.
Pharmacokinetic analysis
Temporal profiles of furosemide in beagle were analyzed
with via non-compartmental model using Phoenix Win-
Nonlin 6.2. (Pharsight, USA). The following pharmacoki-
netic parameters were calculated and compared based
on the route of administration: Cmax, half-life time,
AUCs, CL, Vss, bioavailability (F). The elimination rate
constant (ke) was determined by linear regression of the
semi-log portion of the elimination phase. The elimin-
ation half-life (T1/2) was calculated by dividing 0.693
with ke. The area under the plasma concentration versus
time curve from time zero to time of last measurable
concentration (AUClast), the area under the plasma con-
centration versus time curve from time zero to infinity
(AUCinf) and the area under the respective first moment
time curve from time zero to infinity (AUMCinf) were
calculated based on the linear-up and log-down method.
To estimate the elimination clearance (CL) and volume
of distribution at steady state (Vss), a moment analysis
was conducted. In more detail, CL was gained by divid-
ing administered dose with AUCinf. Vss was obtained by
multiply CL with MRT, which division of AUMCinf by
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AUCinf. Fs of film and tablet groups were calculated
from the dose normalized AUCPO/AUCIV, respectively.
Statistical methods
All data were expressed as mean and standard deviation.
Normality test was conducted with Kolmogorov-
Smirnov test and pharmacokinetic parameters were an
independent t-test. Because the study aimed to compare
orally uncoated tablet with orally disintegrating film,
only the differences between these two formulations of
administration were statistically analyzed. Comparisons
between baseline (0 h) and various time phases after
drug administration were analyzed statistically using the
paired t-test. A P-value < 0.05 was considered to be sta-
tistically significant. Statistical analysis was performed
using SPSS 25 (SPSS Inc., Chicago, IL, USA).
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